We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+3.52%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.69B
AUM Growth
-$46.5M
Cap. Flow
-$20.4M
Cap. Flow %
-1.21%
Top 10 Hldgs %
61.89%
Holding
89
New
22
Increased
14
Reduced
20
Closed
19

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$31.1M
2
BPMC
Blueprint Medicines
BPMC
+$16.9M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$16.3M
4
ZTS icon
Zoetis
ZTS
+$15.3M
5
ZYME icon
Zymeworks
ZYME
+$13.7M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$25.4M
2
BIIB icon
Biogen
BIIB
+$25.4M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$19.8M
4
PODD icon
Insulet
PODD
+$19.2M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$17.8M

Sector Composition

Rank Sector Weight
1 Healthcare 91.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
51
Amarin Corp
AMRN
$287M
$5.46M 0.32%
53,498
-5,031
-9% -$494K
RGNX icon
52
Regenxbio
RGNX
$629M
$5.35M 0.32%
127,593
-300,147
-70% -$10.8M
PTGX icon
53
CALL
Protagonist Therapeutics
PTGX
$8.77B
$5.32M 0.31%
+300,000
New +$12.8M
PTGX icon
54
Protagonist Therapeutics
PTGX
$8.77B
$5.28M 0.31%
297,709
-151,373
-34% -$6.45M
GH icon
55
Guardant Health
GH
$19.3B
$5M 0.3%
+40,000
New +$4.75M
JNCE
56
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$4.74M 0.28%
637,347
+12,591
+2% +$78K
SRRA
57
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$4.53M 0.27%
206,564
+204,064
+8,163% +$4.08M
CYT
58
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$4.32M 0.26%
246,321
-18,679
-7% -$349K
ISEE
59
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.15M 0.25%
+255,300
New +$2.78M
NVCR icon
60
CALL
NovoCure
NVCR
$2B
$3.48M 0.21%
+30,000
New +$4.54M
ICPT
61
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$2.82M 0.17%
+190,000
New +$3.04M
QURE icon
62
uniQure
QURE
$2.65B
$2.52M 0.15%
78,742
-245,561
-76% -$7.49M
PDSB icon
63
PDS Biotechnology
PDSB
$36.8M
$2.13M 0.13%
142,635
– –
ALGS icon
64
Aligos Therapeutics
ALGS
$25.2M
$1.93M 0.11%
4,974
-1,588
-24% -$628K
MRNS
65
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.9M 0.11%
166,711
-179,449
-52% -$2.47M
SYBX
66
DELISTED
Synlogic
SYBX
$1.75M 0.1%
38,331
– –
FULC icon
67
Fulcrum Therapeutics
FULC
$248M
$1.44M 0.09%
+51,006
New +$966K
FUSN
68
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$618K 0.04%
+78,066
New +$657K
PODD icon
69
Insulet
PODD
$11.5B
$303K 0.02%
1,066
-67,434
-98% -$19.2M
ACAD icon
70
CALL
Acadia Pharmaceuticals
ACAD
$4.37B
– –
-100,000
Closed -$2.44M
AGIO icon
71
Agios Pharmaceuticals
AGIO
$2.25B
– –
-219,033
Closed -$12.1M
AMGN icon
72
Amgen
AMGN
$204B
– –
-40,500
Closed -$9.87M
ARKG icon
73
PUT
ARK Genomic Revolution ETF
ARKG
$1.54B
– –
-250,000
Closed -$23.1M
BCRX icon
74
BioCryst Pharmaceuticals
BCRX
$2.49B
– –
-158,609
Closed -$2.51M
CHRS icon
75
Coherus Oncology
CHRS
$225M
– –
-434,555
Closed -$6.01M
1 2
3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q3 2021 Portfolio in Review

As of Q3 2021, Sofinnova Investments held 89 positions worth $1.69B, down 2.7% from $1.74B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Sofinnova Investments's Q3 2021 filing shows 22 new, 14 increased, 20 reduced and 19 closed positions. Its largest new stake was AbbVie: 272,600 shares worth $29.4M. The largest sale was Acceleron Pharma, an estimated $25.4M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 94% a quarter earlier.

  • Sofinnova Investments's largest Q3 2021 buy was AbbVie: 272,600 shares worth $29.4M.
  • Sofinnova Investments added most to Heron Therapeutics in Q3 2021, an estimated $10.1M increase.
  • Sofinnova Investments's biggest Q3 2021 reduction was Acceleron Pharma, cutting an estimated $25.4M.
  • Sofinnova Investments fully exited Neurocrine Biosciences in Q3 2021, selling an estimated $19.8M.
  • Sofinnova Investments's ten largest holdings make up 62% of its $1.69B portfolio in Q3 2021.
  • Sofinnova Investments opened 22 new positions and closed 19 in Q3 2021.
  • Sofinnova Investments's portfolio value fell 2.7% quarter-over-quarter to $1.69B.

Based on Sofinnova Investments's 13F filing for Q3 2021, filed 15 Nov 2021.